As can be seen in Figure 5B, research on AML-targeted therapy focused on MLL-rearranged leukemia (cluster #1), TET2 mutations (cluster #9), and DNA methyltransferase cluster #11) from 2007 to 2013. Here, TET2 is linked to acute myeloid leukemia.